Clinical Trial Update: SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB). [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating intermittent long-term treatment with Pegasys (peginterferon alfa-2a, 40 kDa) in patients with HBeAg-negative chroni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2016-04-11